v3.25.3
Revenue
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Revenue REVENUE
The Company develops, manufactures and sells devices designed for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves. These devices are marketed to a broad base of medical centers globally. The Company recognizes revenue when control of promised goods is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods.
United States revenue by product type is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
Open ablation $35,592$30,601$105,368$90,661
Minimally invasive ablation 7,42811,11723,74735,263
Pain management20,83716,31459,27544,059
Appendage management45,45037,420132,649111,257
Total United States$109,307$95,452$321,039$281,240
International revenue by product type is as follows:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2025202420252024
Open ablation $10,852$8,607$30,196$25,679
Minimally invasive ablation 1,8621,6816,2475,559
Pain management2,0801,5905,9023,768
Appendage management10,1688,58030,64424,784
Total International $24,962$20,458$72,989$59,790
Revenue attributed to customer geographic locations is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
United States$109,307$95,452$321,039$281,240
Europe15,17012,21545,50136,193
Asia Pacific8,0836,91422,35119,916
Other International1,7091,3295,1373,681
Total International24,96220,45872,98959,790
Total Revenue$134,269$115,910$394,028$341,030